OCUPOcuphire Pharma, Inc.

Nasdaq ocuphire.com


$ 1.84 $ 0.21 (12.8 %)    

Thursday, 02-May-2024 15:49:56 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 1.85
$ 1.80
$ 0.00 x 0
$ 0.00 x 0
$ 1.80 - $ 1.97
$ 1.50 - $ 6.60
663,166
na
39.94M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-08-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-04-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-24-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 10-29-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 02-21-2020 12-31-2019 10-K
18 11-06-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-02-2018 09-30-2018 10-Q
23 08-03-2018 06-30-2018 10-Q
24 05-04-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
26 11-03-2017 09-30-2017 10-Q
27 08-04-2017 06-30-2017 10-Q
28 05-03-2017 03-31-2017 10-Q
29 02-24-2017 12-31-2016 10-K
30 11-04-2016 09-30-2016 10-Q
31 08-05-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 03-14-2016 12-31-2015 10-K
34 11-02-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 03-16-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
39 08-13-2014 06-30-2014 10-Q
40 05-14-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ocuphire-pharma-announces-first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-ophthalmic-solution-075-ps-for-the-treatment-of-decreased-visual-acuity-under-low-light-conditions-following-keratorefractive-surgery

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., Apr...

Core News & Articles

 Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...

 design-therapeutics-and-2-other-stocks-under-5-insiders-are-buying

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confid...

 alliance-global-partners-maintains-buy-on-ocuphire-pharma-lowers-price-target-to-20

Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target...

 hc-wainwright--co-reiterates-buy-on-ocuphire-pharma-maintains-20-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...

 ocuphire-pharma-q4-2023-gaap-eps-0210-vs-0050-estimate-sales-1700m

Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.210) per share which missed the analyst consensus estimate of $(...

 ocuphire-pharma-strengthens-leadership-team-with-key-appointments-nirav-jhaveri-cfa-mba-appointed-as-chief-financial-officer

Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief...

 ocuphire-pharma-announces-presentation-on-apx3330-at-the-annual-angiogenesis-exudation-and-degeneration-2024-conference

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...

 ocuphire-pharma-announces-appointment-of-joseph-schachle-mba-as-chief-operating-officer

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...

 hc-wainwright--co-reiterates-buy-on-ocuphire-pharma-maintains-20-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...

 ocuphire-pharma-announces-appointment-of-george-magrath-md-mba-ms-as-chief-executive-officer-and-director

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...

 ocuphire-pharma-inc-gets-nda-approval-from-fda-for-ryzumvi-type-3---new-dosage-form

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217064

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION